格隆汇2月11日丨百济神州(06160.HK)公告，公司将于2026年2月26日(星期四)(即香港联交所交易时间 后)报告其根据美国公认会计原则及美国证券交易委员会适用规则编制的2025年第四季度及全年的财务 业绩。公司董事会将于2026年2月26日(香港时间)审阅及批准2025年第四季度及全年的财务业绩。 财务业绩发布后，公司将于美国东部时间2026年2月26日(星期四)上午八时正(即香港时间2026年2月26日 (星期四)下午九时正)举行电话会议。 ...

财务业绩发布后，公司将于美国东部时间2026年2月26日(星期四)上午八时正(即香港时间2026年2月26日 (星期四)下午九时正)举行电话会议。 格隆汇2月11日丨百济神州(06160.HK)公告，公司将于2026年2月26日(星期四)(即香港联交所交易时间 后)报告其根据美国公认会计原则及美国证券交易委员会适用规则编制的2025年第四季度及全年的财务 业绩。公司董事会将于2026年2月26日(香港时间)审阅及批准2025年第四季度及全年的财务业绩。 ...

財務業績發佈後，本公司將於美國東部時間2026年2月26日（星期四）上午八時正 （即香港時間2026年2月26日（星期四）下午九時正）舉行電話會議。 電話會議將以網路直播方式進行，網絡直播鏈接可從本公司網站的投資者關係頁 面訪問，網址為 https://ir.beonemedicines.com 。為確保及時連接，建議與會者在預 定的網絡直播前至少15分鐘進行註冊。本公司網站將提供業績電話會議網絡直播 的存檔回放。 本公司另將於2026年3月31日或之前公佈其根據香港聯合交易所有限公司證券 上市規則（「香港上市規則」）編製的截至2025年12月31日止年度的經審核財務業 績，此全年業績預計將與根據美國公認會計原則和美國證券交易委員會適用規則 編製的年度業績相同，但香港上市規則所要求的指定附加資料以及將本公司的年 度業績從美國公認會計原則與國際財務報表準則進行核對的結果除外。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines ...

Core Viewpoint - The recent surge in "A+H" listings has seen over 100 A-share companies at various stages of seeking listings in Hong Kong, with a notable presence of biopharmaceutical companies like Kexing Pharmaceutical, which has submitted its application for dual listing [1][2]. Company Overview - Kexing Pharmaceutical, established in 1989 and restructured into a joint-stock company in 2019, is headquartered in Jinan, Shandong [4][3]. - The actual controller of the company, Deng Xueqin, holds 56.27% of the voting rights as of October 2025 [5]. - The board of directors consists of eight members, including four executive directors [6]. Financial Performance - Kexing Pharmaceutical's revenue has fluctuated in recent years, with figures of 1.31 billion, 1.26 billion, 1.40 billion, and 700 million RMB reported for 2022, 2023, 2024, and the first half of 2025, respectively [25]. - The company achieved profitability in 2024, with net profits of 27.05 million RMB and 78.96 million RMB in the first half of 2025 [26]. - Sales expenses have been high, totaling 2.369 billion RMB over three and a half years, while R&D expenses were approximately 788 million RMB, accounting for 16.8% of total revenue [27]. Product Portfolio - Kexing Pharmaceutical has established a product matrix consisting of commercialized products, a research pipeline, and introduced products [9][12]. - The company has four main commercialized products, including SINOGEN, which holds a 55.2% market share in China's short-acting interferon α1b market [10][11]. - The revenue from these products for the years 2022, 2023, 2024, and the first half of 2025 was 1.314 billion, 1.254 billion, 1.392 billion, and 680 million RMB, respectively [12]. Research and Development - Kexing Pharmaceutical has a pipeline of 5 products in clinical stages and 10 in preclinical stages, focusing on oncology, autoimmune diseases, and degenerative diseases [13][18]. - The company has developed a "3KX technology platform" to enhance the R&D process, integrating various advanced technologies [14]. - The most advanced products in the pipeline are GB05 and GB-K02, both currently in Phase III clinical trials [19][20]. Market Position and Challenges - The company is facing challenges due to a lack of blockbuster products and a relatively weak R&D capability compared to other biotech firms [30]. - The sales team may struggle with centralized management due to a dispersed pipeline layout, leading to higher sales expenses [30].

Core Insights - The Chinese innovative drug industry is entering a new decade of development in 2025, with a significant increase in business development (BD) transactions, reaching a total value of $135.655 billion and 157 transactions, both setting historical records, indicating the growing global appeal of Chinese innovative drugs [1] - Milestone payments from previously established collaborations are beginning to materialize, providing cash flow relief for companies and marking substantial progress in global development [1] - However, potential risks associated with BD collaborations are emerging, including the premature termination of agreements and disputes leading to arbitration or litigation, signaling a need for caution in the industry [1] Industry Trends - The surge in BD transactions in 2025 is driven by the long-accumulated innovative potential of China's biopharmaceutical sector, with expectations for continued growth in cross-border transactions between China and the US/Europe [2] - The BD trend began in 2022, but many companies have not yet experienced the full lifecycle of BD transactions, leading to potential undisclosed issues in long-term performance [2] - The period from 2026 to 2028 may see an increase in BD disputes, as the industry transitions from rapid growth to a more regulated and mature phase [2] Financial Highlights - In May 2025, a record-breaking upfront payment of $12.5 billion was secured by a collaboration between Sangamo Therapeutics and Pfizer, with potential total payments reaching $48 billion [3] - In July 2025, China National Pharmaceutical Group announced a $300 million milestone payment from Merck for a collaboration on a PD-1/VEGF dual antibody [3] - In October 2025, a $250 million milestone payment was triggered for a collaboration between SystImmune and Bristol-Myers Squibb, marking the largest single milestone payment for an ADC asset disclosed in China [3] Payment Structures - The "upfront payment + milestone + sales royalty" model remains the dominant approach for Chinese companies in BD transactions, but only 22% of biopharmaceutical companies achieved milestone events by mid-2025, a decrease from previous years [4] - Among 128 transactions with at least one milestone node, 45% did not generate any revenue, highlighting the uncertainty of milestone payment realizations [4] - Increasing the proportion of upfront payments to secure immediate cash flow has become a consensus among companies to mitigate risks [4] Contractual Strategies - Companies are advised to enhance negotiation strategies by creating competitive environments and optimizing milestone payment terms to reduce ambiguity and disputes [5][6] - Specific, quantifiable conditions for milestone payments should be established to minimize subjective interpretations and risks of disputes [5] - The interrelation of contractual terms should be considered to avoid imbalances in rights and obligations, which could lead to significant disagreements during project execution [6] Legal Considerations - The potential for a wave of litigation in the BD sector is rising, driven by long-term contracts and various uncertainties affecting performance [7] - Companies often prioritize commercial negotiations to resolve disputes, but if unsuccessful, they must rely on the agreed dispute resolution mechanisms, emphasizing the importance of precise contract language [7][8] - Early identification of dispute trajectories and effective crisis management can significantly influence the outcome of legal proceedings [8] Future Outlook - As of January 2026, 17 BD transactions have occurred, totaling $133.61 billion, with significant projects continuing to emerge [9] - The ADC sector, small nucleic acid drugs, and in vivo CAR-T therapies are expected to be key areas for BD transactions in the next 1-2 years, with a shift in focus towards clinical data validation [10] - The industry is moving towards a more mature and regulated phase, with an emphasis on risk awareness and compliance as essential elements for successful cross-border BD initiatives [10]

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report highlights significant advancements in the pharmaceutical industry, particularly in the development and approval of innovative drugs, with a focus on oncology and immunotherapy [5][6][10]. Summary by Sections 1. Latest Policy Updates - The National Medical Products Administration (NMPA) has issued several key announcements, including guidelines to strengthen the supervision of entrusted drug production and the release of the 2025 Clinical Application Guidelines for Antitumor Drugs [10][15][18]. - New regulations aim to support the development of innovative drugs and ensure the quality and safety of pharmaceuticals through enhanced management practices [11][12][14]. 2. Domestic New Drug Approvals - In January 2026, a total of 172 new drugs were approved for clinical trials, a decrease of 55 from the previous month. Among these, 78 were chemical drugs, 88 were biological products, and 6 were traditional Chinese medicines [22][23]. - The majority of new drug approvals were in the fields of oncology and immune modulation, accounting for 53% of the total [22]. 3. Global Innovative Drug Development - The report lists several drugs that have shown positive clinical results, including Neumora Therapeutics' NMRA-511 and GSK's new hepatitis B drug, which achieved success in phase 3 studies [6][10]. - Notable approvals include the BCL-2 inhibitor from BeiGene, which received dual indications for chronic lymphocytic leukemia and mantle cell lymphoma [40][41]. 4. New Drug Listings - The report details new drug listings, including the approval of the combination drug for ADHD treatment by Aikobai, which has shown significant efficacy in clinical trials [41][43]. - The approval of Merck's drug for pulmonary arterial hypertension represents a new treatment option that addresses the underlying causes of the disease rather than just symptomatic relief [40].

Core Insights - The current fiscal and monetary policies are in a "honeymoon period," with a strong emphasis on "fiscal-financial coordination" to enhance overall policy effectiveness [2] - Protecting bank net interest margins is a core goal of monetary policy, with a focus on lowering bank funding costs and maintaining favorable credit interest rates [3] - Maintaining low volatility in the bond market is a desirable market objective, with measures to balance government bond supply and demand [4] Fiscal and Monetary Policy - The report highlights the importance of fiscal and monetary policy coordination, stating that monetary policy has an "indirect incentive effect" while fiscal policy has a "direct incentive effect" [2] - The report indicates that the net investment of 5 trillion yuan through reverse repos and MLF in 2025 will effectively supplement the medium- and long-term funding gap [3] Insurance Sector - The insurance sector is expanding its balance sheet as a result of counter-cyclical policies, with premium income projected at 6.1 trillion yuan in 2025, a 7.4% year-on-year increase, while total assets are expected to grow by 15.1% [4] Industry Focus - The report emphasizes the importance of the consumer and pharmaceutical sectors, particularly the "online retail industry" and the pharmaceutical industry's core competitiveness [5] - The pharmaceutical sector is expected to enhance its international competitiveness through cross-border R&D cooperation and overseas clinical trials [5] Asset Management and Banking - The report discusses the shift of deposits from banks to non-bank financial institutions, indicating a trend where asset management products and bank deposits exhibit a "mutual exclusion" dynamic [5] - It is noted that the differentiation among banks is significant, with smaller banks facing challenges in attracting deposits due to lack of recognition from non-bank buyers [6] Market Trends - The report mentions the recent issuance of convertible bonds, with a notable 8 billion yuan issuance by Zhongke Zhuguang, reflecting changes in the supply-demand structure of the convertible bond market [8][9] - The report highlights the performance of the Hong Kong innovation drug sector, which saw a significant rebound, driven by strategic partnerships and market dynamics [24][31]

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Group 1 - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board performing well, particularly in AI applications and computing power chips [1][25] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][29] - The Hong Kong Medical ETF (159137) also performed well, gaining 2.1% and achieving six consecutive days of increases [3][29] Group 2 - The innovation drug sector is benefiting from a surge in business development (BD) overseas and commercial success, with major collaborations announced, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [6][29] - Over 70% of innovative drug companies are expected to achieve positive revenue growth in 2025, with notable companies like BeiGene reporting revenues exceeding 36 billion yuan [7][30] - The Chinese innovative drug industry is entering a phase of commercial success and internationalization, with a focus on the entire industry chain, including CXO and research services [7][30] Group 3 - ByteDance's recent releases, including the Seedance 2.0 video generation model and the Seedream 5.0 image generation model, have positively impacted the Sci-Tech Artificial Intelligence ETF (589520), which saw a price increase of 1.81% [10][31] - The ETF's composition includes significant holdings in domestic AI companies, with ByteDance accounting for over 29% of the index [11][35] - Analysts are optimistic about AI investment opportunities, citing increased capital expenditures from tech giants and a growing demand for AI applications [11][35] Group 4 - The semiconductor and storage chip sectors are experiencing a "super cycle," with companies like Chipone Technology reaching historical highs [15][38] - The global memory price is expected to surge by 80% to 90% in Q1 2026, driven by AI demand, with the storage market projected to reach $551.6 billion [17][39] - The semiconductor equipment industry is also on the rise, with total sales expected to grow by 26% in 2026, indicating a strong market outlook [17][40]

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]